SynthesisBMC nephrology2025
The protective effects of Nicorandil on renal function in patients undergoing coronary interventions: a systematic review and meta-analysis.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-induced nephropathy (CIN) is a serious complication in patients undergoing cardiac interventions, especially in patients with chronic kidney disease. This study aims to assess the efficacy of Nicorandil in CIN reduction and its impact on renal function outcomes.
methodsA comprehensive search was conducted from inception to September, 2024 across four databases. Randomized controlled trials (RCTs) assessing the efficacy of Nicorandil for patients undergoing coronary procedures were included.
resultsBased on analysis of 11 clinical trials involving 2837 patients, Nicorandil significantly reduced the incidence of CIN compared to control group (RR = 0.37, 95%CI [0.27 to 0.49], P < 0.001) without heterogeneity. Nicorandil group was superior to control group in reducing the rise in serum creatinine level at 24, 48 and 72 h (MD= -4.45 umol/L, 95%CI [-7.94 to -0.97], P = 0.01), (MD= -5.57 umol/L, 95%CI [-8.95 to -2.20], P < 0.001) and (MD= -5.70 umol/L, 95%CI [-9.57 to -1.82], P = 0.004) respectively. However, there was no statistically significant difference between Nicorandil group and control group regarding estimated glomerular filtration rate (eGFR) measured at 24, 48 and 72 h (MD = 2.17, 95%CI [-2.03 to 6.37], P = 0.31), (MD = 1.89, 95%CI [-0.15 to 3.93], P = 0.17) and (MD = 2.26, 95%CI [-0.37 to 4.89], P = 0.09) respectively. Nicorandil showed no statistically significant difference between both groups regarding any major adverse event, including stroke, myocardial infarction, conversion to emergency Percutaneous Coronary Intervention (PCI), or urgent need for dialysis.
conclusionNicorandil had an effective role in reducing the incidence of CIN, lower rise in creatinine, and a good safety profile in patients undergoing coronary interventions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.